Richard Lofgren Interview...Episode 72 of the Invention Stories Podcast
The ICR on Twitter: "Professors Kevin Harrington and Alan Melcher (ICR + @royalmarsdenNHS) featured earlier in a @BBCr4today segment on #immunotherapy. In the UK you can still listen to today's live program
Professor Kevin Harrington | The Royal Marsden
Professor Kevin Harrington - The Institute of Cancer Research, London
Professor Kevin Harrington - The Institute of Cancer Research, London
Prof Kevin Harrington | Events | Imperial College London
ICR researchers named among world's most influential scientists - The Institute of Cancer Research, London
The ICR on Twitter: "Professor Kevin Harrington introduces our world-leading work on #immunotherapy, and how we are finding new ways to tackle melanomas, head and neck, and other cancers #partneringtodefeatcancer https://t.co/Q2nRhOW9c7" /
ICR Discovery Club showcases how we combine therapies to target hard-to-treat cancers - The Institute of Cancer Research, London
The ICR on Twitter: "Professor Kevin Harrington introduces our world-leading work on #immunotherapy, and how we are finding new ways to tackle melanomas, head and neck, and other cancers #partneringtodefeatcancer https://t.co/Q2nRhOW9c7" /
Immunotherapy for recurrent or metastatic HNSCC: What are the practical considerations? - touchONCOLOGY
The ICR on Twitter: "🧬 The ICR's Professor Kevin Harrington and his team are using viral #Immunotherapy to harness the body's immune system to kill cancer. See their research with T-VEC, a
Professor Kevin Harrington - The Institute of Cancer Research, London
Get A-Head Visit The Institute of Cancer Research - Get Ahead
BBC Two - Trust Me, I'm a Doctor, Series 3, Episode 3 - Could viral immunotherapy be a revolution in cancer treatment?
Professor Kevin Harrington - The Institute of Cancer Research, London
Professor Kevin Harrington - The Institute of Cancer Research, London
Immunotherapy for recurrent or metastatic HNSCC: What are the practical considerations? - touchONCOLOGY
The ICR on Twitter: "Today, Prof. Kevin Harrington (ICR/@cancerBRC) will present on a trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined
Targeted Physical Therapies | TRM CancerBRC
The ICR on Twitter: "Professor Kevin Harrington explained the basic principles of using viruses to treat cancer and talked about the cancer-killing virus therapy, T-VEC. Find out more about how viral immunotherapies
Using imaging to predict and improve responses to immunotherapy - Oracle Cancer Trust
